% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Palleis:283042,
      author       = {Palleis, Carla and Franzmeier, Nicolai and Gnoerich,
                      Johannes and Jäck, Alexander and Bernhardt, Alexander M and
                      Katzdobler, Sabrina and Fietzek, Urban and Weidinger, Endy
                      and Frontzkowski, Lukas and Roemer-Cassiano, Sebastian and
                      Zwergal, Andreas and Barthel, Henryk and Sabri, Osama and
                      Levin, Johannes and Höglinger, Günter U and Brendel,
                      Matthias},
      title        = {{C}linical value of 18 {F}‐{PI}2620‐{PET} in the
                      diagnostic workup of patients with suspected {P}rogressive
                      {S}upranuclear {P}alsy},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {S2},
      issn         = {1552-5260},
      reportid     = {DZNE-2025-01449},
      pages        = {e102121},
      year         = {2025},
      abstract     = {Background:Progressive Supranuclear Palsy (PSP) is a
                      rapidly progressing 4-repeat tauopathy, presenting with
                      clinically heterogeneous phenotypes. Currently, diagnoses
                      are based solely on clinical criteria but reliable
                      diagnostic classification remains particularly challenging
                      at early stages. 18F-PI-2620 tau-PET is an evolving
                      neuroimaging biomarker to capture 4-repeat tau (4RT)
                      deposits in vivo with clear diagnostic potential in research
                      settings. To determine the added clinical value of
                      18F-PI-2620 tau-PET in the diagnostic workup of PSP, we
                      evaluated whether 18F-PI-2620-assessed 4RT positivity (i.e.
                      using the basal ganglia as a target readout) predicts
                      subsequent increases of diagnostic certainty for PSP,
                      indicative of 4RT pathology driving clinical
                      progression.Method:We collected monocentric longitudinal
                      data at the LMU Hospital in Munich, from a non-randomized
                      prospective cohort study between October 2018 and December
                      2024. Data collection included pre-PET visits with routine
                      clinical classification following the MDS criteria. In
                      addition, we performed 18F-PI-2620 tau-PET with dichotomous
                      visual read assessments of 4RT pathology by an expert reader
                      and collected clinical follow-up data or autopsy
                      information.Results:342 patients with a pre-PET differential
                      diagnosis of PSP were referred to 18F-PI-2620 tau-PET in
                      clinical routine. Of those, 200 patients $(61.5\%$ male,
                      mean±sd age 69.2±8.3 years) had a post-PET clinical
                      follow-up between 12-24 months (mean±sd 17.1±4.2 months).
                      137 patients $(68.5\%)$ were rated 4RT-positive at baseline
                      (Figure 1). The distribution of certainty of PSP diagnosis
                      at baseline and at follow-up is displayed in Figure 2
                      $(A\&B:$ all PSP phenotypes; $C\&D:$ PSP-Richardson Syndrome
                      [RS]; $E\&F:$ variant PSP subtypes). Change to a non-PSP
                      diagnosis at follow-up occurred in $23.5\%,$ identified by a
                      negative baseline tau-PET in $95.5\%.$ In contrast, $79\%$
                      of tau-PET-positive patients with suggestive PSP progressed
                      to a higher diagnostic certainty, $3\%$ had
                      histopathological confirmation of PSP diagnosis, $13\%$
                      remained suggestive PSP, and $5\%$ received a non-PSP
                      diagnosis at follow-up.Conclusion:18F-PI-2620 tau-PET can
                      successfully identify patients that progress along expected
                      4RT clinical spectra. This supports 18F-PI-2620 tau-PET as a
                      4RT biomarker, with the potential to facilitate early
                      biomarker-based diagnosis when clinical criteria may still
                      lack sensitivity and specificity. This development can be
                      transformative for clinical decision making, pre-symptomatic
                      identification of PSP and stratifying patients for disease
                      modifying clinical trials.},
      month         = {Jul},
      date          = {2025-07-27},
      organization  = {Alzheimer’s Association
                       International Conference, Toronto
                       (Canada), 27 Jul 2025 - 31 Jul 2025},
      keywords     = {Humans / Supranuclear Palsy, Progressive: diagnostic
                      imaging / Supranuclear Palsy, Progressive: diagnosis /
                      Supranuclear Palsy, Progressive: metabolism / Male / Female
                      / tau Proteins: metabolism / Biomarkers: metabolism /
                      Positron-Emission Tomography / Aged / Longitudinal Studies /
                      Prospective Studies / Middle Aged / Disease Progression /
                      tau Proteins (NLM Chemicals) / Biomarkers (NLM Chemicals)},
      cin          = {AG Haass / Clinical Research (Munich) / AG Levin / AG
                      Höglinger},
      ddc          = {610},
      cid          = {I:(DE-2719)1110007 / I:(DE-2719)1111015 /
                      I:(DE-2719)1111016 / I:(DE-2719)1110002},
      pnm          = {352 - Disease Mechanisms (POF4-352) / 353 - Clinical and
                      Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-352 / G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)1 / PUB:(DE-HGF)16},
      doi          = {10.1002/alz70856_102121},
      url          = {https://pub.dzne.de/record/283042},
}